Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.

Revenue
+1,349.1%
EPS
+13.3%
Free cash flow
−43.5%

Quarter to June 2026, against a year earlier

276.75 14.16 +5.39%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a

Praxis Precision Medicines, Inc. 8-K/A filed Feb 10, 2026

Period ended Feb 6, 2026 · Filed · accepted 4:52 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov